Novonesis (Novozymes) A/S

Research Novonesis (Novozymes) A/S (NSIS-B) on Bullrun: valuation model: 7.0% overvalued, market cap DKK 191.95B, P/E 43.1, dividend yield 1.6%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNSIS-B
• ExchangeCO
• CountryDenmark
• SectorBasic Materials
• IndustrySpecialty Chemicals
• CurrencyDKK
• Valuation signal7.0% overvalued
• Market capDKK 191.95B
• P/E43.1
• Dividend yield1.6%
• Financial periodFY2025
• RevenueEUR 4.16B
• Revenue growth8.5%
• Net incomeEUR 583.60M
• Free cash flowEUR 811.70M
• Gross margin53.9%

Valuation Snapshot

Bullrun's latest valuation model marks Novonesis (Novozymes) A/S as 7.0% overvalued; latest market cap is DKK 191.95B; P/E is 43.1; dividend yield is 1.6%.

About Novonesis (Novozymes) A/S

Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel;

Frequently asked questions

Is Novonesis (Novozymes) A/S overvalued or undervalued?

Bullrun's valuation model currently marks Novonesis (Novozymes) A/S as 7.0% overvalued.

What is Novonesis (Novozymes) A/S's market cap?

Novonesis (Novozymes) A/S's market capitalization is DKK 191.95B.

What is Novonesis (Novozymes) A/S's P/E ratio?

Novonesis (Novozymes) A/S's price-to-earnings (P/E) ratio is 43.1.

Does Novonesis (Novozymes) A/S pay a dividend?

Novonesis (Novozymes) A/S has a dividend yield of 1.6%.

What does Novonesis (Novozymes) A/S do?

Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America.